Apitegromab: Preserving Muscle During GLP-1 Weight Loss

Significant Lean Mass Loss with GLP-1s: Studies indicate that 25-40% of the total weight lost through GLP-1 therapies comes from lean body mass, which includes vital muscle tissue.

Apitegromab's Role: A new investigational monoclonal antibody, apitegromab, effectively preserves lean mass by selectively inhibiting myostatin, a protein that typically limits muscle growth.

Clinical Evidence: A randomized, double-blind, placebo-controlled Phase 2 trial (EMBRAZE) involving 102 adults demonstrated that participants receiving apitegromab alongside tirzepatide experienced 54.9% greater retention of lean mass compared to those on tirzepatide and placebo, despite similar overall weight loss.

Why This Matters: Lean body mass is critical for physical strength, maintaining a higher metabolic rate, and improving insulin sensitivity, thus lowering the risk of type 2 diabetes. Preserving muscle ensures better functionality and overall health outcomes during weight loss. Prof. Alexander Miras, an obesity expert, notes that while GLP-1s improve functionality, muscle loss can impede activities like lifting heavy weights or walking uphill. Apitegromab could further enhance functionality.

Q: What is Apitegromab and how does it work?

A: Apitegromab is an investigational monoclonal antibody that selectively inhibits myostatin, a protein responsible for limiting muscle growth. By blocking myostatin, it helps preserve lean muscle mass during weight loss.

Q: How does Apitegromab address muscle loss with GLP-1 drugs?

A: When combined with GLP-1 drugs like tirzepatide, apitegromab significantly reduces the proportion of lean mass lost, allowing for a greater percentage of total weight loss to come from fat.

Q: Is Apitegromab safe?

A: In the Phase 2 EMBRAZE trial, apitegromab was well-tolerated, with an incidence of adverse events similar to placebo. Most side effects were mild and consistent with those seen with tirzepatide. However, larger and longer studies are needed to fully assess long-term safety and efficacy.

Q: What is "Ozempic butt"?

A: "Ozempic butt" is a popular term describing the rapid and sometimes dramatic loss of fat and muscle tissue, particularly in the buttocks, observed in some individuals undergoing rapid weight loss with GLP-1 medications.

Hope for Muscle Preservation: Apitegromab offers encouraging early evidence as a potential solution to mitigate the undesirable lean mass loss associated with GLP-1 weight loss therapies, moving towards a healthier body composition.

Prioritize Lean Mass: Maintaining muscle is crucial not only for aesthetics but also for metabolic health, physical strength, and overall well-being.

Current Recommendations: For those currently using GLP-1 drugs, it's essential to complement medication with healthy eating habits, adequate protein intake (20-40g per meal), and regular strength training (two or more sessions per week), which can include activities like lifting weights, resistance band exercises, heavy gardening, or yoga.

Future of Weight Management: While promising, this research is in its early stages. Continued large-scale studies are necessary to fully understand apitegromab's long-term benefits and to determine who might benefit most from this treatment.

Pratley, R. E., Denham, D. S., Trivedi, R., et al. (2026). Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial. *Nature Medicine*. Available at: https://www.nature.com/articles/s41591-026-04440-4?ref=yanuki.com{target="_blank"}

Davis, N. (2026). Muscle growth drug ‘could reduce loss of lean tissue’ when using slimming jabs. *The Guardian*. Available at: https://www.theguardian.com/science/2026/jun/08/muscle-growth-drug-apitegromab-reduce-loss-lean-tissue-slimming-jabs-weight-loss?ref=yanuki.com{target="_blank"}

Roberts, M. (2026). New drug to stop 'Ozempic butt' muscle loss side effect of obesity jabs. *BBC News*. Available at: https://www.bbc.com/news/health-65823773?ref=yanuki.com{target="_blank"}